Shares in Sorrento Therapeutics (SRNE) edged 5% higher in Friday’s after-hours trading, after the company announced that it has now prepaid in full its outstanding term loans on June 12, 2020.The debt, comprised of an initial $100 million term loan and an additional $20 million term loan from funds affiliated with Oaktree Capital Management, L.P, was entered into in November 2018.The news follows the biopharma’s filing of a prospectus supplement dated April 27 for a public offering of up to $250 million of its common stock. Shares are being sold via Alliance Global Partners, alongside a 36-month purchase agreement with …read more
Source:: Yahoo Finance
